Abstract
Background
The risk for colorectal adenoma and advanced adenoma among diabetes mellitus II (DM II) has been debated to differ with the type of anti-diabetic therapy. Insulin increases whereas metformin decreases the risk for colon adenoma (Ad) and advanced Ad (AAd). There have been no studies to evaluate the effect of combination treatment with insulin and metformin on colon Ad and AAd.
Methods
The retrospective study included DM II patients undergoing screening colonoscopy. Subjects with incomplete colonoscopy, poor bowel preparation, personal history of colorectal cancer (CRC)/inflammatory bowel disease/hereditary nonpolyposis colorectal cancer/familial adenomatosis polyposis/colectomy or family history of CRC were excluded. Subjects were categorized into group 1 (insulin only), group 2 (metformin only), group 3 (combination of insulin and metformin) and group 4 (miscellaneous). Group 4 was excluded from data analysis. Ad detection rate (ADR) and advanced ADR (AADR) were calculated for each group.
Results
Three hundred thirty-nine subjects composed the study group, with a mean age of 60.0 years and male to female ratio of 1:1.4. Composite ADR and AADR for study population was 35.1 and 15.3 %, respectively. Groups 1, 2 and 3 were composed of 88 (26.0 %), 211 (62.2 %) and 40 (11.8 %) subjects, respectively. ADR for groups 1, 2 and 3 was 40.9, 33.2 and 32.5 %, respectively (p value = 0.413). AADR for groups 1, 2 and 3 was 18.2, 15.2 and 10.0 %, respectively (p value = 0.489).
Conclusion
A decremental trend was observed in ADR and AADR across group 1, group 2 and group 3 (p value >0.05).
Similar content being viewed by others
References
Bond JH. Clinical evidence for the adenoma-carcinoma sequence, and the management of patients with colorectal adenomas. Semin Gastrointest Dis. 2000. PMID:11057945
Ries LAG, Eisner MP, Kosary CL et al. SEER Cancer Statistics Review, 1975-2002, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2002/, based on November 2004 SEER data submission, posted to the SEER web site 2005.
Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM. Colorectal Cancer Screening Guidelines. doi:10.1038/ajg.2009.104
Eddi R, Karki A, Shah A, DeBari VA, DePasquale JR. Association of type 2 diabetes and colon adenomas. J Gastrointest Cancer. 2012. doi: 10.1007/s12029-011-9316-7. PMID:21894459
Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr. 2007. PMID:18265477
Kim BC, Shin A, Hong CW et al. Association of colorectal adenoma with components of metabolic syndrome. Cancer Causes Control. 2012;23. doi: 10.1007/s10552-012-9942-9. PMID:22450737
Elwing JE, Gao F, Davidson NO, Early DS. Type 2 diabetes mellitus: the impact on colorectal adenoma risk in women. Am J Gastroenterol. 2006. doi:10.1111/j.1572-0241.2006.00651.x. PMID:16790036
Yang Y-X, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 127:1044–1050. DOI: http://dx.doi.org/10.1053/j.gastro.2004.07.011. PMID:15480982
Wong P, Weiner MG, Hwang WT, Yang YX. Insulin therapy and colorectal adenomas in patients with diabetes mellitus. Cancer Epidemiol Biomarkers Prev. 2012;Epub 2012 Aug. doi: 10.1158/1055-9965.EPI-12-0771. PMID:22879206
Zhou G, Myers R, Li Y et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167–1174. doi:10.1172/JCI13505. PMID:11602624
Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009, 32(9):620-625. Epub 2009 Jun 29. doi: 10.2337/dc08-2175. PMID:19564453
Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009, 52(9):1766. Epub 2009 Jul 2. doi: 10.1007/s00125-009-1440-6. PMID:19572116
Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. Journal of the National Cancer Institute. 2005;97(22):1679–87. doi: 10.1093/jnci/dji375 PMID:16288121
Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. Journal of the National Cancer Institute. 2002;94(13):972–80. doi: 10.1093/jnci/94.13.972. PMID:12096082
Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr. 2001;131(11 Suppl):3109S–20S. PMID:11694656
LeRoith D, Baserga R, Helman L, Roberts CT. Insulin-like growth factors and cancer. Annals of Internal Medicine. 1995;122(1):54–9. comment. doi:10.7326/0003-4819-122-1-199501010-00009. PMID:7619109
Renehan AG, Painter JE, Atkin WS, Potten CS, Shalet SM, O’Dwyer ST. High-risk colorectal adenomas and serum insulin-like growth factors. British Journal of Surgery. 2001;88(1):107–13. doi:10.1046/j.1365-2168.2001.01645.x.
Teramukai S, Rohan T, Lee K-Y, Eguchi H, Oda T, Kono S. Insulin-like growth factor (IGF)-I, IGF-binding protein-3 and colorectal adenomas in Japanese men. Japanese Journal of Cancer Research. 2002;93(11):1187–94. PMID:12460458
Renehan AG, Painter JE, O’Halloran D et al. Circulating insulin-like growth factor II and colorectal adenomas. J Clin Endocrinol Metab. 2000;85(9):3402–8. DOI: http://dx.doi.org/10.1210/jcem.85.9.6770. PMID:10999841
Schoen RE, Weissfeld JL, Kuller LH et al. Insulin-like growth factor-I and insulin are associated with the presence and advancement of adenomatous polyps. Gastroenterology. 2005;129(2):464–75. DOI: http://dx.doi.org/10.1053/j.gastro.2005.05.051. PMID:16083703
Shaw RJ, Lamia KA, Vasquez D et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005;310:1642–6. DOI:10.1126/science.1120781. PMID:16308421
Zhang ZJ, Zheng ZJ, Kan H et al. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care. 2011;34(10):2323-8. doi: 10.2337/dc11-0512. Review. PMID: 21949223
Higurashi T, Takahashi H, Endo H et al. Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial. BMC Cancer. 2012; 12: 118. Published online 2012 March 26. doi: 10.1186/1471-2407-12-118. PMCID: PMC3353167
Yang YX, Habel LA, Capra AM et al. Serial glycosylated hemoglobin levels and risk of colorectal neoplasia among patients with type 2 diabetes mellitus. Cancer Epidemiol Biomarkers Prev. 2010;19(12):3027-36. doi: 10.1158/1055-9965.EPI-10-0486. Epub 2010 Oct 11. PMID: 20937982
Authors’ Contributions
Dr. Jain designed the study, collected the data, analysed the data results and wrote the manuscript. Dr. Chhoda did the statistical analysis for the collected data and reviewed and edited the manuscript. Dr. Uribe reviewed and edited the manuscript.
Guarantor of the Article
Deepanshu Jain, MD
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Financial Support
None.
Conflict of Interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Jain, D., Chhoda, A. & Uribe, J. Effect of Insulin and Metformin Combination Treatment on Colon Adenoma and Advanced Adenoma Among DM II. J Gastrointest Canc 47, 404–408 (2016). https://doi.org/10.1007/s12029-016-9842-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12029-016-9842-4